Differences in breast carcinoma immunohistochemical subtypes between immigrant arab and european women

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Preat, Fanny ^a   Simon, Philippe ^a   Noel, Jean Christophe ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Arab; Breast carcinoma; European; Immunohistochemistry; Luminal A; Luminal B; Molecular classification

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARAB; ARTICLE; BREAST TUMOR; CARCINOMA; CAUCASIAN; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MIGRANT; ONSET AGE; PATHOLOGY;

AGE OF ONSET; ARABS; BREAST NEOPLASMS; CARCINOMA; EMIGRANTS AND IMMIGRANTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893155767     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-26     Document Type: Article

References (25)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
2. McPherson K, Steel CM, Dixon JM. Breast cancer: epidemiology, risk factors and genetics. BMJ 2000, 321:624-628. 10.1136/bmj.321.7261.624, 1118507, 10977847.
3. Bernstein L, Teal CR, Joselyn S, Wilson J. Ethnicity-related variation in breast cancer risk factors. Cancer 2003, 97:222-229. 10.1002/cncr.11014, 12491485.
4. Chouchane L, Boussen H, Satry K. Breast cancer in Arab populations: molecular characteristics and disease management implications. Lancet Oncol 2013, 14:417-424.
5. Teebi AS, Teebi SA. Genetic diversity among the Arabs. Community Genet 2005, 8:21-26. 10.1159/000083333, 15767750.
6. El Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, Mesbahi O, Amarti A. Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. Diagn Pathol 2012, 7:170. 10.1186/1746-1596-7-170, 3538531, 23216981.
7. WHO classification of tumours of the breast. 2012, Lyon, France: IARC Press, Lakhani SR, Ellis IO, Schnitt SJ, Hoon Tan P, van de Vijver MJ.
8. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osbome CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep F, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2074-2795.
9. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes C, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Viale G, Zujewski JA, Hayes DF. Assessment of Ki-67 in breast cancer: recommendations from the international KI67 in Breast Cancer working group. J Natl Cancer Inst 2011, 103:1656-1664. 10.1093/jnci/djr393, 3216967, 21960707.
10. Schrohl AS, Pedersen HC, Jensen SS, Nielsen S, Brünner N. Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology 2011, 59:975-983. 10.1111/j.1365-2559.2011.04034.x, 3263426, 22092409.
11. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett J, Bilous M, Fitzgibbons P, Hanna W, Jenkins R, Mangu P, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2013, 31:3997-4013. 10.1200/JCO.2013.50.9984, 24101045.
12. Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States 1999-2004. Cancer Epidemiol Biomarkers Prev 2009, 18:1763-1769. 10.1158/1055-9965.EPI-08-1082, 19454615.
13. El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F, Seould M, Shamseddine AL. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 2007, 5:225-233. 10.1016/j.ijsu.2006.06.015, 17660128.
14. Boulos S, Gadallah M, Neguib S, Essam E, Youssef A, Costa A, Mittra I, Miller AB. Breast screening in the emerging world: high prevalence of breast cancer in Cairo. Breast 2005, 14:340-346. 10.1016/j.breast.2005.07.002, 16131468.
15. Bujassoum SM, Gehani AA. Epidemiology of breast cancer in Qatar 1999-2002. Qatar Med J 2004, 13:43-45.
16. El-Zaemey S, Nagi N, Fritschi L, Heyworth J. Breast cancer among Yemeni women using the National Oncology Centre Registry 2004-2010. Cancer Epidemiol 2012, 36:249-253. 10.1016/j.canep.2012.01.006, 22377278.
17. Azaiza F, Cohen M. Health beliefs and rates of breast cancer screening among Arab women. J Womens Health 2006, 15:520-530.
18. Mellon S, Gauthier J, Cichon M, Hammad A, Simon MS. Knowledge, attitude and beliefs of Arab-American women regarding inherited cancer risk. J Genet Couns 2013, 22:268-276. 10.1007/s10897-012-9546-2, 3799781, 23054337.
19. Kawar LN. Barriers to breast cancer screening participation among Jordanian and Palestinian American women. Eur J Oncol Nurs 2012, 1:88-94.
20. Missaoui N, Jaidene L, Abdelkrim SB, Abdelkader A, Beizig N, Yaacoub LB, Yaacoubi MT, Hmissa S. Breast cancer in Tunisia: clinical and pathological findings. Asian Pac J Cancer Prev 2011, 12:169-172.
21. Al-Kuraya K, Schraml P, Skeik S, Amr S, Torhost J, Tapia C, Novotny H, Spichtin H, Maurer R, Mislacher M, Simon R, Sauter G. Predominance of high grade pathway in breast cancer development of Middle East women?. Mod Pathol 2005, 18:891-895. 10.1038/modpathol.3800408, 15803183.
22. Cakir A, Gonul I, Uluoglu O. A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas. Diagn Pathol 2012, 7:145. 10.1186/1746-1596-7-145, 3488514, 23082819.
23. Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, Hartie T, Eisen M, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese J, Brown P, Botstein D, Eystein Lonning P. Gene expression patterns of breast carcinoma distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
24. Goldhirsch A, Wood W, Coates AS, Gelber R, Thurslimann B, Senn H. Strategies for subtypes-dealing with diversity of breast cancer: highlights of the St Gallen International expert consensus on primary therapy of early breast cancer 2011. Ann Oncol 2011, 22:1736-1747. 10.1093/annonc/mdr304, 3144634, 21709140.
25. Chalabi N, Bernard-Gallon DJ, Bignon Y. Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor bit significative biological differences. Cancer Genomics Proteomics 2008, 5:253-261.